Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The Rockwell Medical (RMTI) news feed on Stock Titan focuses on company announcements that relate to its hemodialysis concentrates portfolio, supply agreements with dialysis providers, operational updates, and financial results.
Investors and healthcare observers following RMTI news can expect coverage of product purchase agreements with large dialysis providers, health systems, and specialized care organizations. Recent company communications describe multi-year contracts that include utilization or purchase minimums, options to renew, and supply of liquid and dry acid and bicarbonate concentrates, as well as Rockwell Medical’s dry acid concentrate mix system and bicarbonate cartridge. News items also highlight the company’s efforts to expand its customer base, including adding new dialysis customers in different regions of the United States.
The RMTI news stream also includes quarterly financial and operational results, typically released through earnings press releases and accompanied by conference call details. These updates discuss net sales, gross margin, adjusted EBITDA, and cash position, along with commentary on customer transitions, contract renewals, and manufacturing efficiency. In addition, Rockwell Medical issues news on leadership changes, such as board appointments and executive promotions, and on operational roles related to manufacturing and supply chain management.
Further topics in Rockwell Medical news include participation in industry events, such as exhibiting its hemodialysis concentrates portfolio at professional nephrology conferences, and recognition as a Great Place to Work® and a Fortune Best Workplaces in Manufacturing & Production™ honoree. For users tracking RMTI, this news page provides a centralized view of the company’s corporate developments, financial disclosures, and updates on its hemodialysis products and customer relationships.
Rockwell Medical (Nasdaq: RMTI) has promoted Jesse Neri to Chief Financial Officer. Neri, who joined the company in October 2023 as SVP of Finance, brings nearly 25 years of financial leadership experience in both public and private companies. Prior to Rockwell, he served as Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, and as Senior Vice President of Finance at Zyla Life Sciences, where he managed a $80 million revenue operation and led various strategic initiatives including product acquisitions and commercial launches.
Rockwell Medical (RMTI) has announced a partnership with HydroCare, a provider of dialysis water treatment systems, to distribute and install Rockwell's dry acid concentrate mix system in dialysis water rooms. The partnership involves HydroCare purchasing and installing Rockwell's DAMX45 system, which is 510(k) approved for exclusive use with the company's CitraPure® and Dri-Sate® dry acid concentrate powders.
The DAMX45 system features a forced RO water pump that can mix 100 gallons of acid concentrate on-site in three minutes. This collaboration is expected to generate new sales for Rockwell's dry acid hemodialysis concentrates through expanded mixer installations.
Rockwell Medical (Nasdaq: RMTI) has entered into an exclusive distribution agreement with Nephro Group Dialysis Centers, the largest dialysis provider in the Philippines. Under the agreement, Rockwell Medical will be the exclusive supplier of dry hemodialysis concentrates products, including CitraPure® Acid and RenalPure® Bicarbonate. Nephro Group, founded in 1995, has grown to become the Philippines' largest dialysis provider. This expansion adds to Rockwell Medical's international presence, which now spans over 30 countries across North America, South America, Asia, and Africa.
Rockwell Medical (RMTI) reported strong Q3 2024 financial results with net product sales of $28.3 million, up 31% year-over-year. The company achieved gross profit of $6.2 million (183% increase) and a gross margin of 22%. Notable highlights include $4.3 million in cash flow from operations and net income of $1.7 million. The company increased its 2024 guidance, projecting net sales of $98-101 million and Adjusted EBITDA of $4-5 million. However, their largest customer indicated expected volume declines in 2025, potentially reducing sales by $31-38 million.
Rockwell Medical (Nasdaq: RMTI) has rescheduled its third quarter 2024 earnings release and conference call to Tuesday, November 12, 2024, due to SEC EDGAR system closure on November 11 for Veterans Day. The company will issue its financial and operational results press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET. The call will discuss Q3 2024 results and include a Q&A session.
Rockwell Medical, Inc. (Nasdaq: RMTI), a healthcare company specializing in hemodialysis products, has announced the release of its third quarter 2024 financial and operational results on Monday, November 11, 2024. The company will issue a press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET.
The conference call details are as follows:
- Date: Monday, November 11, 2024
- Time: 8:00am ET
- Live Number: (888) 660-6347 (US) / 1 (929) 201-6594 (International)
- Conference Call ID: 4944610
- Webcast and Replay: www.RockwellMed.com/Results
Rockwell Medical, Inc. (Nasdaq: RMTI), a healthcare company specializing in hemodialysis products, has been recognized as one of the 2024 Fortune Best Workplaces in Manufacturing and Production in the small & medium category. This prestigious acknowledgment comes from Great Place to Work® and Fortune magazine.
Lesley Spriggs, Vice President of Human Resources at Rockwell Medical, expressed pride in the company's achievement, highlighting the dedication of their leadership and employees. The company's focus on manufacturing and delivering life-sustaining dialysis solutions for patients with end-stage kidney disease has been a key factor in this recognition.
Rockwell Medical (Nasdaq: RMTI) has announced a product purchase agreement with the leading at-home and acute care dialysis provider in the United States. The company will supply its RenalPure® liquid acid and SteriLyte® liquid bicarbonate hemodialysis concentrates to the customer. These products will be packaged in either four-per-case for larger dialysis settings or two-per-case for smaller acute care and at-home care settings.
Rockwell Medical's convenience pack, which includes two 1-gallon pre-mixed containers of either RenalPure or SteriLyte, offers advantages such as easier handling and streamlined workflow for home patients, caregivers, healthcare providers, and acute facilities. This agreement supports the customer's patient-centric care model and addresses the growing demand for technological advancements in the dialysis space, particularly in the underserved at-home hemodialysis segment.
Rockwell Medical (Nasdaq: RMTI) has entered into a multi-million dollar distribution agreement with Nipro Medical The agreement allows Nipro to distribute Rockwell's hemodialysis concentrates and mixer globally, excluding the United States. Key points:
- Two-year agreement with a one-year extension option
- Minimum product purchases of $5.0 million for the first year with incremental increases thereafter
- Covers liquid and dry acid concentrates, bicarbonate concentrates, and dry acid concentrates mixer
- Aims to meet increasing market demand for Rockwell's hemodialysis products
- Expands accessibility to Rockwell's products for dialysis patients worldwide
Rockwell Medical (RMTI) reported strong financial results for Q2 2024, achieving profitability on a cash flow and Adjusted EBITDA basis. Net sales increased 43% to $25.8 million, while gross profit surged 341% to $4.6 million. The company improved its gross margin to 18% from 6% in the same period last year. Notably, Rockwell generated $1.4 million in cash flow from operations.
The company raised its 2024 guidance, now expecting net sales between $95 million and $98 million. Rockwell projects mid-to-high single-digit growth in 2025 and beyond, with gross margins expected to reach above 25% by 2026. The positive results were driven by organic growth in hemodialysis concentrates products, streamlined production, and new customer contracts.
FAQ
What is the current stock price of Rockwell Med (RMTI)?
What is the market cap of Rockwell Med (RMTI)?
